Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
企業コードBBLGW
企業名Bone Biologics Corp
最高経営責任者「CEO」Mr. Jeffrey Frelick
ウェブサイトhttps://www.bonebiologics.com/
よくある質問
Bone Biologics Corp(BBLGW)の現在の株価はいくらですか?
Bone Biologics Corp(BBLGW)の現在の株価は9.000です。
Bone Biologics Corpのティッカーシンボルは何ですか?
Bone Biologics CorpのティッカーシンボルはBBLGWです。
Bone Biologics Corpの52週高値はいくらですか?
Bone Biologics Corpの52週高値は7.740です。
Bone Biologics Corpの52週安値はいくらですか?
Bone Biologics Corpの52週安値は1.300です。
Bone Biologics Corpの時価総額はいくらですか?
Bone Biologics Corpの時価総額は--です。
Bone Biologics Corpの純利益はいくらですか?
Bone Biologics Corpの純利益は--です。
Bone Biologics Corp (BBLGW) の現在の評価は「買い」、「ホールド」、「売り」のどれですか?